RHEUMATOLOGY
Daniel Solomon, MD, MPH, on Interleukin-1 Blockade to Prevent Gout Attacks
08/05/2019
Daniel Solomon, MD, MPH, from Brigham and Women's Hospital, discusses what rheumatologists should know about interleukin-1β inhibitors, findings from his study of canakinumab for the prevention of gout, and more.
Daniel Solomon, MD, MPH, is a professor of medicine at Harvard Medical School and chief of clinical science in the Division of Rheumatology at Brigham and Women’s Hospital in Massachusetts.
Read more about Dr Solomon’s study here.